Navigation Links
Uroplasty Reports Fiscal Fourth Quarter And Full Year 2013 Financial Results
Date:5/30/2013

MINNEAPOLIS, May 30, 2013 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today reported financial results for the fourth quarter and fiscal year 2013 ended March 31, 2013. 

Fiscal Fourth Quarter 2013 Financial ResultsFiscal fourth quarter 2013 sales in the U.S. increased 2%, driven by an 11% increase in sales of the Urgent® PC Neuromodulation System, compared with fiscal fourth quarter a year ago.  Global sales declined 1% to $5.5 million in the fourth quarter of fiscal 2013, compared with $5.6 million in the fiscal fourth quarter a year ago.

U.S. Urgent PC Sales in the fiscal fourth quarter of 2013 were $2.6 million.  Macroplastique sales in the U.S. totaled $1.4 million in the recent fiscal fourth quarter, a decrease of 13% over the same quarter last year.

The Company sold 3,365 lead set boxes to 581 active Urgent PC customers in the U.S. in the fiscal fourth quarter compared with 3,501 lead set boxes to 620 active customers during the fiscal third quarter. 

"While sales of Urgent PC in the U.S. increased year over year, we were disappointed with our progress," said Rob Kill, Interim Chief Executive Officer of Uroplasty. "We are executing our strategy to reinvigorate and regain the momentum of Urgent PC sales, especially in the U.S.  By mid-May, under our new sales leadership, we had replaced sales representatives in six territories. We are focused on finding sales representatives with experience in medical device sales, a solid understanding of their regional markets and strong relationships with physician groups in their territories. By end of June we expect to have 45 total sales representatives in place."

Net sales to customers outside the U.S. for the fiscal fourth quarter totaled $1.5 million, compared to $1.6 million in the fiscal fourth quarter last year.  Excluding the impact of fluctuations in foreign currency exchange rates, sales outside the U.S. were down 7%. 

The Company reported a gross margin of 86.5% in the recent fiscal fourth quarter compared with 85.9% in the same quarter a year ago.  The operating loss of $968,000 in the fiscal fourth quarter compares with a $589,000 operating loss in the same quarter last year. Excluding non-cash charges for share-based compensation and depreciation and amortization expense, the non-GAAP operating loss was $477,000 in the fourth quarter of fiscal 2013, compared with a $122,000 non-GAAP operating loss in the fourth quarter a year ago.  The increase in operating loss was primarily attributable to the decrease in sales and an increase in operating expenses.

Full Year Fiscal 2013 Financial ResultsFor the full year ended March 31, 2013, sales grew $1.9 million to $22.4 million, reflecting an 18% increase in U.S. sales and a 10% decrease in sales outside the U.S.  In the U.S., sales of Urgent PC increased 35% to $10.5 million, and Macroplastique sales decreased 2% to $5.7 million.  At March 31, 2013, cash, cash equivalents and investments totaled $14.9 million compared to $15.6 million at December 31, 2012.

R&D InitiativesThe Company continues to make progress on two R&D initiatives - an implantable tibial nerve stimulator for in-home treatments for OAB for the markets outside of the U.S. and an indication for use of Urgent PC to treat bowel incontinence for the U.S. market.  Both products have the potential to expand Uroplasty's addressable market.

The implantable tibial nerve stimulator will allow patients to receive the benefits of PTNS treatments at home with the patient controlling the treatment interval.  The Company continues to make progress on prototypes for this new product.

The Company has identified two U.S. centers to conduct a pilot clinical trial for the treatment of bowel incontinence using the Urgent PC Neuromodulation System.  The investigators at those centers are currently in the screening process for potential candidates for treatment.  The pilot trial, for the initial treatments, is scheduled for completion late next year.  Urgent PC has CE Mark approval for the treatment of bowel incontinence and has been used in Europe for this indication for several years. 

Outlook"Our focus in the near term will be on driving sales of Urgent PC through additional investments in sales and marketing. We made progress in the quarter in hiring experienced sales reps with strong relationships in their markets and have also revised our sales incentives to be better aligned with our financial objectives.  We are also adding clinical representatives to the team who will focus on working with our customers to expand patient access to Urgent PC.  We anticipate it will take a few months for our new reps to become productive.

"In addition, we have commenced a search for a new CEO.  Working with an outside search firm, we are seeking a senior executive with experience in leading the commercial expansion of new medical device therapies and scaling an organization in the $25 to $200 million range of revenue for sustained top and bottom line growth.  We remain optimistic about the opportunities ahead for Uroplasty through this transition and our ability to return to sales growth and improved operating results during the second half of the fiscal year," concluded Mr. Kill.

Conference CallUroplasty will host a conference call and webcast today at 3:30 pm Central, 4:30 pm Eastern, to review the financial results for the fiscal fourth quarter and full year of 2013.  Rob Kill, Interim Chief Executive Officer, and Medi Jiwani, Vice President, Chief Financial Officer and Treasurer, will host. Individuals wishing to participate in the conference call should dial 888-549-7750. An audio replay will be available for 30 days following the call at 800-406-7325 with the passcode 4618943#.

To access the live webcast of the call, go to Uroplasty's website at www.uroplasty.com and click on the Investor Relations section. An archived webcast will also be available at http://investor.uroplasty.com.

About Uroplasty, Inc. Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a global medical company committed to offering transformative treatment options to specialty physicians. Our products are designed to help providers change the lives of their voiding dysfunction patients and strengthen the efficiency of their practices. Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared system that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique®, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.

Forward-Looking InformationThis press release contains forward-looking statements that reflect our best estimates regarding future events and financial performance. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results. We discuss in detail the factors that may affect the achievement of our forward-looking statements in our Annual Report on Form 10-K filed with the SEC.  In particular, we cannot be certain that we will ever achieve sustained profitability, that the rate of reimbursement for PTNS treatments will be adequate to justify the cost of our product, that other Medicare carriers or private payers will provide coverage for this treatment or that existing carriers and payers will not change their coverage decisions, that the rate of adoption of our products by new customers will continue, or that any of the other risks identified in our 10-K will not adversely affect our expectations as described in these forward-looking statements.For Further Information: Uroplasty, Inc.

Medi Jiwani, Vice President, CFO,

and Treasurer

952.426.6140

EVC Group

Jenifer Kirtland (Investors)

415.568.9349

Amy Phillips (Media)

412.327.9499  

 

UROPLASTY, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONSThree Months EndedYear EndedMarch 31,March 31,(unaudited)2013201220132012Net sales

$5,540,586$5,596,782$22,417,980$20,561,714Cost of goods sold 

750,165791,5273,014,8863,036,967Gross profit

4,790,4214,805,25519,403,09417,524,747Operating expensesGeneral and administrative

1,009,580843,6844,187,8193,732,623  Research and development

719,282406,2962,415,1231,905,366  Selling and marketing

3,814,1943,929,24815,238,60015,296,217  Amortization

215,862215,460862,833856,9955,758,9185,394,68822,704,37521,791,201Operating loss

(968,497)(589,433)(3,301,281)(4,266,454)Other income (expense)  Interest income

10,20314,25446,03960,072  Interest expense

(695)-(707)(57)  Foreign currency exchange gain

5,00518,0841,5733,78014,51332,33846,90563,795Loss before income taxes

(953,984)(557,095)(3,254,376)(4,202,659)Income tax expense 

14,95815,94450,77047,712Net loss

$(968,942)$(573,039)$(3,305,146)$(4,250,371)Basic and diluted loss per common share

$(0.05)$(0.03)$(0.16)$(0.21)Weighted average common shares outstanding:Basic and diluted

20,803,53020,722,91020,777,23820,689,819 

UROPLASTY, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEETSMarch 31, 2013March 31, 2012AssetsCurrent assets:Cash and cash equivalents & short-term investments

$11,470,469$11,854,127Accounts receivable, net

2,553,4472,704,434Inventories

718,933698,742Other

566,536363,639Total current assets

15,309,38515,620,942Property, plant, and equipment, net

1,033,0851,171,979Intangible assets, net 

100,502945,880Long-term investments

3,451,7114,429,140Deferred tax assets

146,052122,872Total assets

$20,040,735$22,290,813Liabilities and Shareholders' Equity  Current liabilities: Accounts payable

$618,916$593,585 Current portion – deferred rent

35,00035,000 Income tax payable

7,72917,892 Accrued liabilities:Compensation

1,550,8461,576,147Other

476,287316,995Total current liabilities

2,688,7782,539,619Deferred rent – less current portion

5,14142,043Accrued pension liability

660,580474,396Total liabilities

3,354,4993,056,058Total shareholders' equity

16,686,23619,234,755Total liabilities and shareholders' equity

$20,040,735$22,290,813 

UROPLASTY, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWSYear EndedMarch 31,20132012Cash flows from operating activities:Net loss

$(3,305,146)$(4,250,371)Adjustments to reconcile net loss to net cash used in operating activities:  Depreciation and amortization

1,152,9291,118,243  Loss on disposal of  equipment

7,6178,447  Amortization of premium on marketable securities

47,55935,277  Share-based consulting expense

1,6235,448  Share-based compensation expense

810,016679,471  Deferred income taxes

(29,053)(40,116)  Deferred rent credit

(36,902)(35,228)  Changes in operating assets and liabilities:  Accounts receivable, net

108,495(653,110)  Inventories

(25,370)(29,719)  Other current assets

(205,778)(17,510)  Accounts payable

30,925(59,025)  Accrued liabilities

138,87563,981  Accrued pension liability, net

79,59845,843Net cash used in operating activities

(1,224,612)(3,128,369)Cash flows from investing activities:Proceeds from maturity of available-for-sale marketable securities

4,200,00010,018,252Proceeds from maturity of held-to-maturity marketable securities

6,920,0003,740,000Purchases of available-for-sale marketable securities

(8,425,034)(3,046,270)Purchases of held-to-maturity marketable securities

(2,500,000)(8,840,000)Purchases of property, plant and equipment

(189,929)(267,944)Proceeds from sale of property, plant and equipment

5,591-Payments for intangible assets

(17,455)(77,738)Net cash provided by (used in) investing activities

(6,827)1,526,300Cash flows from financing activities:Net proceeds from exercise of options

150,000208,825Net cash provided by financing activities

150,000208,825Effect of exchange rate changes on cash and cash equivalents

(37,923)(17,103)Net decrease in cash and cash equivalents

(1,119,362)(1,410,347)Cash and cash equivalents at beginning of period

4,653,2266,063,573Cash and cash equivalents at end of period

$3,533,864$4,653,226Cash paid during the period for interest

$707$57Cash paid during the period for income taxes

57,28839,005Non-GAAP Financial Measures:  The following table reconciles our operating loss calculated in accordance with accounting principles generally accepted in the U.S. (GAAP) to non-GAAP financial measures that exclude non-cash charges for share-based compensation, and depreciation and amortization expenses from gross profit, operating expenses and operating loss.  The non-GAAP financial measures used by management and disclosed by us are not a substitute for, or superior to, financial measures and consolidated financial results calculated in accordance with GAAP, and you should carefully evaluate our reconciliations to non-GAAP.  We may calculate our non-GAAP financial measures differently from similarly titled measures used by other companies.  Therefore, our non-GAAP financial measures may not be comparable to those used by other companies.  We have described the reconciliations of each of our non-GAAP financial measures described above to the most directly comparable GAAP financial measures.

We use these non-GAAP financial measures, and in particular non-GAAP operating loss, for internal managerial purposes and incentive compensation for senior management because we believe such measures are one important indicator of the strength and the operating performance of our business.  Analysts and investors frequently ask us for this information.  We believe that they use these measures to evaluate the overall operating performance of companies in our industry, including as a means of comparing period-to-period results and as a means of evaluating our results with those of other companies.

Our non-GAAP operating loss for the three months ended March 31, 2013 and 2012 was approximately $477,000 and $122,000, respectively.  Our non-GAAP operating loss for fiscal 2013 and 2012 was approximately $1.3 million and $2.5 million, respectively.  The fiscal 2013 decrease in non-GAAP operating loss is attributed primarily to an increase in Net sales which more than offset the increase in non-GAAP spending. 

 Expense AdjustmentsGAAPShare-based
ExpenseDepreciationAmortization
of IntangiblesNon-GAAPThree Months Ended March 31, 2013Gross Profit

$4,790,000

$8,000

$8,000$4,806,000% of net sales

86.5%86.8%Operating ExpensesGeneral and administrative

1,009,000

(133,000)

(50,000)826,000Research and development

719,000

(14,000)

(1,000)704,000Selling and marketing

3,814,000

(47,000)

(14,000)3,753,000Amortization

216,000

0

0

$(216,000)

05,758,000

(194,000)

(65,000)

(216,000)

5,283,000Operating Loss

$(968,000)

$202,000

$73,000

$216,000

$(477,000)Three Months Ended March 31, 2012Gross Profit

$4,805,000

$6,000

$9,000$4,820,000% of net sales

85.9%86.1%Operating ExpensesGeneral and administrative

844,000

(116,000)

(44,000)684,000Research and development

406,000

(9,000)

(1,000)396,000Selling and marketing

3,929,000

(51,000)

(16,000)3,862,000Amortization

215,000$(215,000)

-5,394,000

(176,000)

(61,000)

(215,000)

4,942,000Operating Loss

$(589,000)

$182,000

$70,000

$215,000

$(122,000)Expense AdjustmentsGAAPShare-based
ExpenseDepreciationAmortization
of IntangiblesNon-GAAPYear Ended March 31, 2013Gross Profit

$19,403,000

$31,000

$34,000$19,468,000% of net sales

86.6%86.8%Operating ExpensesGeneral and administrative

4,188,000

(473,000)

(196,000)3,519,000Research and development

2,415,000

(54,000)

(3,000)2,358,000Selling and marketing

15,238,000

(254,000)

(57,000)14,927,000Amortization

863,000$(863,000)

-22,704,000

(781,000)

(256,000)

(863,000)

20,804,000Operating Loss

$(3,301,000)

$812,000

$290,000

$863,000

$(1,336,000)Year Ended March 31, 2012Gross Profit

$17,525,000

$22,000

$34,000$17,581,000% of net sales

85.2%85.5%Operating ExpensesGeneral and administrative

3,733,000

(412,000)

(163,000)3,158,000Research and development

1,905,000

(39,000)

(9,000)1,857,000Selling and marketing

15,296,000

(212,000)

(55,000)15,029,000Amortization

857,000$(857,000)

-21,791,000

(663,000)

(227,000)

(857,000)

20,044,000Operating Loss

$(4,266,000)

$685,000

$261,000

$857,000

$(2,463,000) 


'/>"/>
SOURCE Uroplasty, Inc.
Copyright©2012 PR Newswire.
All rights reserved


Related medicine technology :

1. Uroplasty Announces Positive Coverage Decision For Percutaneous Tibial Nerve Stimulation By Wisconsin Physicians Services
2. Uroplasty To Announce Fiscal Fourth Quarter And Full Year 2013 Financial Results On May 30, 2013
3. Uroplasty Announces CEO Resignation
4. Uroplasty To Present At The 25th Annual ROTH Growth Stock Conference
5. Uroplasty Announces Executive Changes In US Sales Organization
6. Uroplasty Reports Fiscal Third Quarter 2013 Financial Results
7. Uroplasty To Participate In The Oppenheimer 23rd Annual Healthcare Conference
8. Uroplasty To Participate In Two Upcoming Investor Conferences
9. Uroplasty Reports Fiscal Second Quarter 2013 Financial Results
10. Uroplasty To Participate In Two Upcoming Conferences
11. Uroplasty Reports Fiscal First Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... Amarantus BioScience Holdings, Inc. (OTCQX: AMBS), ... and Orphan Diseases, today announced that President & CEO Gerald ... SeeThru Equity MicroCap Conference   Where: ... , NY When: Tuesday, May 31 st , ... Where: Grand Hyatt Hotel, 109 East 42 nd St, ...
(Date:5/26/2016)... May 26, 2016   Change Healthcare ... analytics, network solutions and technology-enabled services designed ... entered into a strategic channel partnership with ... software solutions and revenue cycle management services ... and rehabilitation clinics to optimize revenue, operational ...
(Date:5/25/2016)... , Germany and GERMANTOWN, ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: ... licensing and co-development agreement with Therawis Diagnostics GmbH to develop ... be to develop and market PITX2 as a marker to ... high-risk breast cancer patients. "We are pleased to ...
Breaking Medicine Technology:
(Date:5/28/2016)... ... , ... SuperCloset is proud to officially launch our “Helping Veterans Grow ... and obstacles veterans’ need to overcome in order to face their life changes upon ... veteran(s) with a donated SuperCloset product based on the needs and ability of helping ...
(Date:5/27/2016)... ... ... More than a third of American adults are considered obese, says the ... increased attention in recent years, as an article published May 18th on ... people are familiar with the basic requirements of maintaining a healthy diet and exercise ...
(Date:5/27/2016)... ... May 27, 2016 , ... With over 60 percent of acute ... for a sustainable product to aid in the rehabilitation process has steadily increased. Ekso ... of individuals with hemiplegia due to stroke. , Ekso Bionics has now received clearance ...
(Date:5/27/2016)... New York, NY (PRWEB) , ... May 27, ... ... health care world, this installment is bolstered by inspiring human interest stories, courtesy ... to the developing trends and tech within the industry, from leading advocates and ...
(Date:5/26/2016)... ... ... There are many ways to cook a hot dog, but new research commissioned ... dogs straight off the grill. Of the 90 percent of Americans who say they ... hot dog, far outpacing other cooking methods such as steaming (12 percent), microwaving (9 ...
Breaking Medicine News(10 mins):